logo-loader

Acasti Pharma expects top-line results on heart disease therapy by year's end

Published: 15:37 06 May 2019 EDT

Acasti Pharma Inc (NASDAQ:ACST) CEO Jan D'Alvise tells Proactive Investors that the Quebec-based biopharma is expecting Phase 3 top-line results by the end of 2019 for its krill oil-derived drug candidate CaPre, which treats severe hypertriglyceridemia, a contributor to heart disease.

D'Alvise says she's excited as she expects the study to show not only a significant triglyceride reduction but also a unique effect on improving glucose metabolism levels in diabetic patients.

Acasti Pharma outlines key benefits of recent Grace Therapeutics acquisition

Acasti Pharma Inc (TSX-V:ACST, NASDAQ:ACST). CEO Jan D’Alvise joined Proactive New York to discuss the Laval, Québec-based group's recent acquisition of Grace Therapeutics including its therapeutic pipeline consisting of three clinical stage and pre-clinical stage assets. D’Alvise walked...

on 10/08/2021